Q&A (CCC-139)

Thursday, October 26, 2023

17:18 – 17:30 EST

Location: Palais, 517D

Target Audience: General: All cardiovascular (clinical and research) health professionals

Co-Chair(s)

Jacob A. Udell, MD, MPH

Cardiology Division Head
Women's College Hospital
University of Toronto
Shelley Zieroth, MD

Heart Failure Cardiologist, Past President CHFS
St. Boniface Hospital
University of Manitoba

Disclosure(s):

Jacob A. Udell, MD, MPH: Boehringer Ingelheim: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Janssen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novovax: Consultant/Advisory Board (Terminated, December 8, 2022); Sanofi: Consultant/Advisory Board (Terminated, May 16, 2022)

Shelley Zieroth, MD: Astra Zeneca: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bayer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); BMS: Consultant/Advisory Board (Ongoing); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Cytokinetics: Consultant/Advisory Board (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); GSK: Consultant/Advisory Board (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing); Otsuka: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Roche: Speaker/Honoraria (Ongoing); Servier: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Vifor: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)